New combo therapy targets tough liver cancer
NCT ID NCT05441475
First seen Mar 01, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests a new drug (ABSK-011) combined with atezolizumab or standard treatments in about 118 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors, especially in patients whose cancers have a specific marker (FGF19 overexpression). Treatment continues until side effects become too severe or the disease worsens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Hubei, Shanghai Municipality, 430030, China
Conditions
Explore the condition pages connected to this study.